Advocacy intelligence hub — real-time data for patient organizations
CAPRELSA(r): FDA approved
Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
CAPRELSA(r)
Genzyme Corporation
CAPRELSA(r)
(vandetanib)Orphan drugGenzyme Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, T...
Browse all Deafness with labyrinthine aplasia, microtia, and microdontia news →
View all Deafness with labyrinthine aplasia, microtia, and microdontia specialists →